At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 32 enrolled
Drug / intervention
Selpercatinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Dose, Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Way Crossover Study to Evaluate the Effect of LOXO-292 on the QTc Interval in Healthy Adult Subjects
In Brief
A Phase 1 clinical trial evaluating Selpercatinib, Moxifloxacin, and 1 other intervention for Healthy. Completed, enrolled 32 participants across 1 site.
Detailed Summary
The main purpose of this study is to assess the effect of Selpercatinib (LY3527723) on the heart rate-corrected QT (QTc) interval. The study will last up to 41 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsLoxo Oncology, Inc.
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
Enrollment StartApr 2019
Primary CompletionJun 2019
First PostedNov 2022
TodayJul 2026
First PostedNov 29, 2022
Enrollment StartApr 16, 2019
Primary CompletionJun 21, 2019
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 3.6 years ago
Interventions
Selpercatinibdrug
Administered orally
Moxifloxacindrug
Administered orally
Placebodrug
Administered orally.